Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: Dave who wrote (33757)	4/28/1999 4:00:00 PM
From: HeatherN	Respond to of 90042

Dave, I appreciate your opinion and your background, but our office is the leading (in terms of numbers) prescriber in the midwest of several current pain medications and we were the largest prescriber of Celebrex in the Chicago area for the first month that it was out( due to our large patient load). It is a good drug, but we have had a significant number of people with GI and other undesirable side effects. The incidence of endoscopy demonstrated gastric ulceration is about half that of more common NSAIDS like naproxen and similar to Relafen. If Vioxx is a better drug with fewer of these weird reactions that we've seen then it will surpass Celebrex. PM me for more discussion. Heather